+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users



Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users



Medicine 94(26): E1047



Antiplatelet drugs are widely used for the prevention of cardiovascular disease and cerebral vascular disorders. Although there have been several studies on gastroduodenal mucosal injury with gastrointestinal (GI) symptoms such as GI bleeding, in antiplatelet drug users (including low-dose aspirin (LDA)), there have been few reports on the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users. This study was a cross-sectional study elucidating the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Subjects were 186 asymptomatic Japanese antiplatelet drug users who underwent a regular health checkup. Subjects were divided into those with and without gastroduodenal mucosal injury endoscopically, and the association between gastroduodenal mucosal injury and other data in asymptomatic antiplatelet drug users was investigated.The prevalence of males and drinkers were significantly higher in subjects with gastroduodenal mucosal injury than in those without. In addition, the prevalence of proton pump inhibitor (PPI) users was significantly lower in subjects with gastroduodenal mucosal injury than in subjects without gastroduodenal mucosal injury. Logistic regression analysis showed PPI (odds ratios: 0.116; 95% confidence intervals: 0.021-0.638; P < 0.05) was a significant predictor of a decreased prevalence of gastroduodenal mucosal injury and closed-type (C-type) atrophy (3.172; 1.322-7.609; P < 0.01) was a significant predictor of an increased prevalence of severe gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Gender and lifestyle, such as drinking, may have an impact on risk of gastroduodenal mucosal injury in asymptomatic subjects taking antiplatelet drugs. Although PPI is a significant predictor of a decreased prevalence of gastroduodenal mucosal injury, including in asymptomatic antiplatelet drug users, status of gastric atrophy should also be considered against severe gastroduodenal mucosal injury.

(PDF emailed within 0-6 h: $19.90)

Accession: 058157775

Download citation: RISBibTeXText

PMID: 26131815

DOI: 10.1097/MD.0000000000001047


Related references

Prevalence of gastroduodenal mucosal injury in asymptomatic patients taking antiplatelet agents in Japan. International Journal of Clinical Pharmacology and Therapeutics 47(12): 722-725, 2010

Gastroduodenal mucosal injury in patients on antiplatelet therapy. Thrombosis Research 120(4): 465-469, 2007

Are Japanese patients more prone to gastro-duodenal mucosal injury and bleeding with the use of antiplatelet agents?. Thrombosis Research 120(4): 463-464, 2007

Low-dose aspirin-induced gastroduodenal mucosal injury in Japanese patients with arteriosclerotic disease. Internal Medicine 49(23): 2537-2545, 2011

Relationship between nonsteroidal anti-inflammatory drug use, Helicobacter pylori, and gastroduodenal mucosal injury. Gastroenterology 113(6 SUPPL ): S85-S89, 1997

Effect of aspirin cessation before endoscopy in Japanese patients with low-dose-aspirin-associated gastroduodenal mucosal injury. United European Gastroenterology Journal 1(4): 259-264, 2014

Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology 99(6): 1616-1621, 1990

The prevalence of gastroduodenal mucosal injuries in aspirin users. Journal of the Medical Association of Thailand 96(11): 1423-1427, 2014

Geranylgeranylacetone, a gastromucoprotective drug, protects against NSAID-induced esophageal, gastroduodenal and small intestinal mucosal injury in healthy subjects: A prospective randomized study involving a comparison with famotidine. Internal Medicine 53(4): 283-290, 2014

Sulglycotide in the prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal mucosal injury. A controlled double-blind, double-dummy, randomized endoscopic study versus placebo in rheumatic patients. Scandinavian Journal of Gastroenterology 28(10): 875-878, 1993

Effects of gastric medicines on gastroduodenal injury in patients with stable angina during antiplatelet therapy. Journal of Cardiology 54(1): 71-75, 2011

Pathways, mediators and mechanisms of gastroduodenal mucosal injury. Acta Physiologica Hungarica 80(1-4): 9-21, 1992

Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Practice and Research. Clinical Gastroenterology 15(5): 691-703, 2001

Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Practice and Research. Clinical Gastroenterology 15(5): 705-722, 2001